SAN FRANCISCO & HOUSTON--(BUSINESS WIRE)--Tachyon Therapeutics, Inc. ("Tachyon" or "the Company"), a private, clinical-stage biotechnology company developing transformative cancer therapies against ...
- First patient enrolled in Phase 1 clinical study of TACH101, a small molecule, KDM4 histone demethylase inhibitor, in patients with advanced or metastatic solid tumors - Tachyon also announces the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback